Theratechnologies CEO John-Michel T. Huss. The company today announced that Health Canada is now reviewing tesamorelin, and expects to receive a decision within 150 days.
About Nick WaddellCantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
